Biotech Startups

Verley Food addresses the global dairy protein deficit by promoting a diversified protein mix that combines conventional farming, precision fermentation proteins, and plant-based products. The company focuses on sustainable protein production solutions to meet rising global demand while ensuring food sovereignty and reducing environmental impact.

1 investor

Vernal Biosciences is an mRNA contract development and manufacturing organization (CDMO) that produces high-quality mRNA for research and therapeutic development. The company serves researchers and biotech companies seeking reliable mRNA supply for drug discovery and clinical applications.

1 investor

Vero BioScience develops a blood-based proteomic test that measures organ-specific protein signatures to assess the biological age of individual organs and detect early signs of age-related disease. The company targets individuals seeking predictive health insights and preventive medicine interventions based on technology developed at Stanford.

1 investor

Verogen provides NGS sequencing systems and reagent solutions for forensic and research laboratories, with offerings including the MiSeq FGx Sequencing System and flexible financing options like leasing, reagent rental programs, and bundled workflows.

1 investor

Verrica Pharmaceuticals is a therapeutics company developing and commercializing treatments for dermatological diseases, including molluscum contagiosum, common warts, and skin cancers such as basal cell and squamous cell carcinoma. Its products serve dermatology prescribers, payers, and patients, with a lead drug-device combination based on topical cantharidin.

1 investor

Publicly listed pharmaceutical company

1 investor

Versant Ventures is a venture capital firm that invests in deep technology and life sciences companies.

1 investor

Verseau Therapeutics discovers and develops macrophage-targeting monoclonal antibodies to enhance anti-tumor immune responses in cancer patients. The company uses a patient-based discovery engine to identify novel targets for immunotherapy, focusing on treating solid tumors where macrophages are prevalent.

1 investor

Vesper is a venture builder in biotechnology that spins out companies in human health and agriculture from early-stage research. The company combines capital deployment, IP structuring, and operational support to commercialize scientific innovations.

1 investor

Vetbiolix develops first-in-class therapeutic drugs for companion animals, specifically targeting osteoarthritis, periodontitis, and gut motility disorders in dogs and cats. The company adapts promising drug candidates from human clinical development stages to the veterinary market.

1 investor

A veterinary pharmaceutical company developing Rabacfosadine, an acyclic nucleotide analogue for treating lymphoma in dogs and cats.

1 investor

VETSTEM develops regenerative cell therapies based on multipotent mesenchymal stem cells (MSCs) and high-bioavailability pharmaceutical products for treating diseases in pets. The company operates in veterinary biotech, applying molecular-cell technologies and pharmaceutical chemistry to animal health.

1 investor

N&E Innovations develops ViKANG, a natural antibacterial agent made from food waste, certified to eliminate bacteria and viruses for use in disinfectants, water treatment, and food-grade plastics. The company operates with a circular economy model to reduce carbon emissions and environmental impact while addressing global health challenges.

1 investor

VIAN Therapeutics develops a topical eye drop treatment for retinal diseases caused by angiogenesis and vascular permeability, offering a non-invasive alternative to intravitreal injections. The lead candidate targets age-related macular degeneration and diabetic macular edema by inhibiting pro-angiogenic factors and inflammatory cytokines.

1 investor

Vicore Pharma is a clinical-stage biopharmaceutical company developing disease-modifying treatments for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis. The company's lead program, buloxibutid, is an oral small molecule in Phase 2b clinical trials.

1 investor

Safetest develops, produces, and sells rapid lateral-flow diagnostic test kits for detecting human diseases through isolation of specific antigens, and offers R&D, antigen/antibody conjugation services, training, and technical support. It positions itself as a Brazilian company making fully domestically produced rapid diagnostic tests for researchers, companies, and healthcare applications.

1 investor

The Global Alzheimer's Platform Foundation is a nonprofit organization that reduces the time and cost of clinical trials for Alzheimer's and Parkinson's disease by coordinating multi-site research networks and providing trial management, data, and participant recruitment services. It serves pharmaceutical sponsors, contract research organizations, and clinical research sites seeking to accelerate neurodegenerative disease drug development.

1 investor

1 investor

Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies in areas such as metabolic and endocrine disorders. This page presents its board of directors.

1 investor

VintaBio provides viral vector manufacturing for clinical and commercial gene therapies, using a single-stream process (VintaProcess) to produce high-yield, high-purity vectors. It offers end-to-end services from discovery through final delivery for cell and gene therapy developers.

1 investor

Viralgen provides contract manufacturing services for AAV-based gene therapy, supporting early-phase preclinical and clinical production with a platform designed for regulatory compliance and batch scalability. The company serves gene therapy developers pursuing treatments for rare diseases.

1 investor

Viramal develops proprietary products for women's sexual, vaginal, and reproductive health using its Fem Med Tech platform. The company targets unmet needs in women's healthcare through a clinically-led approach.

1 investor

Virchu operates a histopathology-powered precision oncology platform that aggregates de-identified whole-slide images and longitudinal patient data to train and validate AI models for cancer detection and treatment. The platform serves oncology researchers and AI developers seeking curated, representative data across multiple cancer types.

1 investor

Vireo Ag offers the Whole Plant Delivery platform, a greenhouse-based plant genome engineering method that edits crops directly in soil without tissue culture, delivering stable seed in a single plant generation. The company licenses its patented tools and collaborates with crop-development companies across food, feed, fuel, and fiber to shorten breeding timelines.

1 investor